Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Recursion

Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

Barchart

Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today

On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the SP 500 slipping nearly 0.6% to 6,753.72. The Dow Jones Industrial Average was unchanged at 46,601.78.These are the top stocks that gained the attention of retail traders and investors through the day: Costco Wholesale…

Benzinga

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce

While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.

Barchart

The AI drug breakthrough is taking a long time to arrive for reasons that may have little to do with the technology’s limits

“No matter how much data you have, human biology is still a mystery,” one analyst said.

Fortune

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know.

Benzinga

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Imagine you stepped into the dimly lit hospital meeting room to pitch a new cancer‑diagnostic deal. You flick through slides powered by Palantir Technologies Inc.'s (NASDAQ:PLTR) Foundry platform, showcasing data transparency and precision that would make legacy pharma pipelines look prehistoric.

Benzinga

Why Is Recursion Pharma Stock Surging On Monday?

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).

Benzinga

Why This Wildcard Stock Could Be a Future Star

Recursion’s slow and steady start could lead to a bright future in biotech.

Barchart

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?

Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares?

Barchart

Should You Buy These 2 Nvidia-Backed Stocks Now?

Is Nvidia’s investment a good reason to buy these stocks?

Barchart

2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

Barchart

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?

Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

MarketBeat

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

MarketBeat

NVIDIA Invested in These 2 AI Stocks, Should You?

Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.

Barchart

1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

AI Could Power Up These 2 Biotech Stocks

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Barchart

Should You Buy the Dip in This AI-Driven Drug Stock?

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

Barchart

3 Small-Cap Stocks Set To Skyrocket

These under-the-radar companies may offer greater long-term rewards.

Barchart

3 Small-Cap Stocks to Invest in AI Drug Development

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

Barchart

1 AI Growth Stock With 54% Upside Potential

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Barchart

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Barchart

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

267 stories

Places

United States

340,611 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.